Heterozygous carriers of BRCA1 or BRCA2 mutations have a 82% lifetime risk of breast cancer, as well as 54 and 23% risks of ovarian cancer, respectively (King et al, 2003). The gene discussed is BRCA2; the disease is ovarian cancer.